NewsRamp Psychedelics Podcast

NewsRamp Psychedelics Podcast

Explore the emerging world of psychedelics with the 'NewsRamp Psychedelics Podcast.' This podcast delivers the latest news and insights from NewsRamp.com, focusing on research developments, therapeutic applications, and regulatory changes in the psychedelics field. Stay informed on the groundbreaking advancements in this evolving industry.

Episodes

Advancements in Mental Health Treatments: NRx Pharmaceuticals and Cybin Inc. Acquisitions and Developments

September 9, 2025 • 2 mins
NRx Pharmaceuticals' subsidiary HOPE Therapeutics Inc. has acquired Dura Medical, a provider of interventional psychiatry services in Florida, expanding its network. Meanwhile, Cybin Inc. has completed enrollment in its Phase 2 study of CYB004 for Generalized Anxiety Disorder, with topline data expected in Q1 2026, aiming to address the needs of millions of Americans living with GAD.
Mark as Played

Cybin Inc. Chief Business Officer to Speak at H.C. Wainwright Conference

September 4, 2025 • 1 min
Cybin Inc., a neuropsychiatry company, will have their Chief Business Officer participating in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference to discuss their focus on developing new treatment options for mental health conditions, including CYB003 in Phase 3 studies for major depressive disorder and CYB004 in a Phase 2 study for generalized anxiety disorder. Established in 2019, Cybin is actively op...
Mark as Played

Fireside Chat with Cybin Inc.'s CMO at Cantor Global Healthcare Conference

September 3, 2025 • 1 min
Cybin Inc.'s Chief Medical Officer, Amir Inamdar, will be participating in a fireside chat at the Cantor Global Healthcare Conference on September 5, 2025, discussing the company's focus on developing new treatment options for mental health conditions such as major depressive disorder and generalized anxiety disorder. The session will be webcast live and available for replay on Cybin's investor relations website. Founded in 2019, C...
Mark as Played

Leadership Changes and Treatment Advancements in Mental Health Companies

September 2, 2025 • 2 mins
Cybin Inc. appoints Eric So as Interim CEO following Doug Drysdale's resignation, focusing on advancing clinical pipeline for mental health conditions. Meanwhile, NRx Pharmaceuticals Inc. secures FDA Fast Track designation for IV ketamine formulation NRX-100 in treating suicidal depression, expanding its potential patient pool.
Mark as Played

Advancing Psilocybin Therapy: Psylutions Supports Rescheduling Efforts

August 28, 2025 • 2 mins
Psylutions, a pioneering cultivator and manufacturer of psilocybin in Colorado, praises the DEA's decision to advance a petition to reschedule psilocybin for scientific review by the U.S. Department of Health and Human Services. This move is seen as a significant stride towards mainstream acceptance of psychedelics in medicine, offering hope for patients in palliative care and Veterans with PTSD. Psylutions is poised to lead the ch...
Mark as Played

Empowering Growth for Ketamine & TMS Clinics: Strategic Partnership Announcement

August 27, 2025 • 2 mins
Ketamine Lead Gen partners with HealingMaps and Healing Health Alliance to support the growth of Ketamine & TMS clinics by providing patient education, digital marketing, and operational solutions. The collaboration aims to enhance clinic profitability and scalability through high-intent patient discovery, measurable marketing strategies, and exclusive benefits for clinic owners.
Mark as Played

Cybin Inc. Receives Approval for Phase 3 Study of CYB003 in Australia

August 27, 2025 • 2 mins
Cybin Inc. has been granted approval to start the EMBRACE Phase 3 study of CYB003 in Australia, marking a significant milestone in their development of new treatment options for mental health conditions. This study is part of Cybin's Phase 3 multinational program, PARADIGM, and focuses on major depressive disorder.
Mark as Played

NRx Pharmaceuticals Urges FDA to Ban Benzethonium Chloride from Ketamine Products

August 22, 2025 • 2 mins
NRx Pharmaceuticals, listed on NASDAQ as NRXP, has filed a Citizen Petition asking the FDA to prohibit the use of benzethonium chloride in ketamine products due to its toxic nature. The company has presented evidence supporting the safety and stability of their preservative-free ketamine, 'NRX-100', and is also seeking FDA approval for their oral NMDA-targeting drug, 'NRX-101'. Learn more about NRx Pharmaceuticals and stay updated ...
Mark as Played

Advancements in Incannex Healthcare Inc.: Positive Phase 2 Results and Strong Valuation Potential

August 21, 2025 • 2 mins
Stonegate Capital Partners' updated coverage on Incannex Healthcare Inc. highlights the positive Phase 2 study results of their IHL-42X asset, showing significant reduction in Apnoea-Hypopnoea Index. Patient-reported outcomes were also impressive, boosting IXHL's prospects for bringing IHL-42X to market. The company's financial position has improved through strategic financing, and other projects like PSX-001 and IHL-675A are progr...
Mark as Played

Cybin Inc. Reports Promising Results and Shareholder Meeting Summary

August 19, 2025 • 1 min
Cybin Inc., a neuropsychiatry company, discussed developments in innovative mental health treatments at their recent shareholder meeting, with a focus on promising data for CYB003 and CYB004. Shareholders representing nearly half of the company's common shares were present. Visit Cybin's newsroom for further details.
Mark as Played

Cybin Inc. Reports Q1 2025 Results and Progress in Depression and Anxiety Studies

August 14, 2025 • 2 mins
Cybin Inc., a clinical-stage neuropsychiatry company, shared its Q1 2025 results and updates on its Phase 3 Depression Program and Phase 2 Anxiety Study. The company has expanded its Phase 3 program for major depressive disorder and is close to completing enrollment for its anxiety study. With adequate funding, Cybin is poised to address the pressing need for improved mental health treatments.
Mark as Played

NRx Pharmaceuticals' HOPE Therapeutics(TM) Expands Network and Expertise with Acquisition of Dura Medical LLC

August 8, 2025 • 2 mins
NRx Pharmaceuticals' subsidiary HOPE Therapeutics(TM) has received regulatory clearance in Florida to acquire Dura Medical LLC, a clinic specializing in mental health and chronic pain treatment. This acquisition will enhance HOPE's presence in Florida and strengthen their capabilities in utilizing psychedelic medications and neuroplastic technologies to treat depression and PTSD. NRx Pharmaceuticals is also progressing with filing ...
Mark as Played

Cybin Inc. Receives European Approval for Phase 3 Study on CYB003 for Major Depressive Disorder

August 7, 2025 • 2 mins
Cybin Inc. has obtained approval to launch the EMBRACE Phase 3 study in Ireland, Poland, and Greece as part of their PARADIGM program. The study will evaluate the efficacy of CYB003, a proprietary deuterated psilocin analog, in treating Major Depressive Disorder by enrolling 330 participants across various international sites. Visit www.cybin.com for more information on Cybin and its innovative mental healthcare research pipeline.
Mark as Played

Revolutionizing Mental Healthcare: Cybin's CEO to Speak at Growth Conference

August 6, 2025 • 2 mins
Cybin Inc., a neuropsychiatry company, will have CEO Doug Drysdale participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference. Cybin is dedicated to developing new treatment options for mental health conditions, with ongoing studies on major depressive disorder and generalized anxiety disorder. A live webcast of the event will be available, showcasing Cybin's commitment to transforming mental healthcare.
Mark as Played

Exploring Neuroplasticity in CNS Disorders with NRx Pharmaceuticals CEO

July 29, 2025 • 2 mins
NRx Pharmaceuticals CEO Prof. Jonathan Javitt will discuss the use of ketamine and other drugs for treating CNS disorders like depression, suicidality, and PTSD at the upcoming BTIG Virtual Biotechnology Conference. The company is focused on developing therapeutics for conditions such as bipolar depression and PTSD, with plans to file for Accelerated Approval for NRX-101 and NRX-100.
Mark as Played

Cybin Inc. Receives UK Approval for Phase 3 Trial in Depression

July 17, 2025 • 2 mins
Cybin Inc. has obtained approval to commence the second Phase 3 trial for CYB003 in Depression, aiming to enroll 330 patients globally. With a focus on psychedelic-based treatments, the company seeks to address the growing demand for innovative mental health therapies, following the success of esketamine in the sector.
Mark as Played

NRx Pharmaceuticals Applies for FDA Priority Voucher for NRX-100

June 27, 2025 • 1 min
NRx Pharmaceuticals, trading as NRXP on NASDAQ, has submitted an application for the FDA Commissioner’s National Priority Voucher for their IV Ketamine product, NRX-100. The company's focus on U.S.-based manufacturing and pursuit of a patent on their preservative-free process could enhance their competitive edge in treating suicidal depression and PTSD.
Mark as Played

Advancing FDA-Designated Therapies: NRx Pharmaceuticals Collaborates with IBN for Corporate Communications Strategy

June 25, 2025 • 1 min
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) partners with IBN to enhance investor awareness as it progresses with FDA-designated therapies NRX-100 and NRX-101 for suicidal depression, chronic pain, and PTSD. The company's NMDA platform shows promise in treating central nervous system disorders, with plans for an NDA filing for NRX-100 and a public spin-out of subsidiary HOPE Therapeutics. Stay updated on NRXP developments at https://i...
Mark as Played

Psyence Biomedical Chief to Speak at Psychedelic Science 2025 Conference

June 18, 2025 • 2 mins
Mary-Elizabeth Gifford, Chief of Global Impact at Psyence Biomedical Ltd., will be a featured speaker at Psychedelic Science 2025, discussing business ethics in the realm of psychedelic research. Psyence Biomedical is a Nasdaq-listed biopharma company focusing on nature-derived psilocybin medicine for FDA approval.
Mark as Played

Advancements in Cybin Inc.'s Phase 3 Psychedelic Therapeutics Program

June 13, 2025 • 2 mins
Cybin Inc. provided an update on its Phase 3 Psychedelic Therapeutics Program, highlighting progress in the clinical pipeline, with the lead candidate CYB003 advancing into Phase 3 development. CEO Doug Drysdale expressed confidence in the company's IP portfolio and clinical strategy, noting positive shifts in regulatory sentiment as a key factor in expediting the review process. Cybin is focused on creating safe and effective psyc...
Mark as Played

Popular Podcasts

    On Purpose with Jay Shetty

    On Purpose with Jay Shetty

    I’m Jay Shetty host of On Purpose the worlds #1 Mental Health podcast and I’m so grateful you found us. I started this podcast 5 years ago to invite you into conversations and workshops that are designed to help make you happier, healthier and more healed. I believe that when you (yes you) feel seen, heard and understood you’re able to deal with relationship struggles, work challenges and life’s ups and downs with more ease and grace. I interview experts, celebrities, thought leaders and athletes so that we can grow our mindset, build better habits and uncover a side of them we’ve never seen before. New episodes every Monday and Friday. Your support means the world to me and I don’t take it for granted — click the follow button and leave a review to help us spread the love with On Purpose. I can’t wait for you to listen to your first or 500th episode!

    NFL Daily with Gregg Rosenthal

    NFL Daily with Gregg Rosenthal

    Gregg Rosenthal and a rotating crew of elite NFL Media co-hosts, including Patrick Claybon, Colleen Wolfe, Steve Wyche, Nick Shook and Jourdan Rodrigue of The Athletic get you caught up daily on all the NFL news and analysis you need to be smarter and funnier than your friends.

    The Joe Rogan Experience

    The Joe Rogan Experience

    The official podcast of comedian Joe Rogan.

    New Heights with Jason & Travis Kelce

    New Heights with Jason & Travis Kelce

    Football’s funniest family duo — Jason Kelce of the Philadelphia Eagles and Travis Kelce of the Kansas City Chiefs — team up to provide next-level access to life in the league as it unfolds. The two brothers and Super Bowl champions drop weekly insights about the weekly slate of games and share their INSIDE perspectives on trending NFL news and sports headlines. They also endlessly rag on each other as brothers do, chat the latest in pop culture and welcome some very popular and well-known friends to chat with them. Check out new episodes every Wednesday. Follow New Heights on the Wondery App, YouTube or wherever you get your podcasts. You can listen to new episodes early and ad-free, and get exclusive content on Wondery+. Join Wondery+ in the Wondery App, Apple Podcasts or Spotify. And join our new membership for a unique fan experience by going to the New Heights YouTube channel now!

    The Bobby Bones Show

    The Bobby Bones Show

    Listen to 'The Bobby Bones Show' by downloading the daily full replay.

Advertise With Us
Music, radio and podcasts, all free. Listen online or download the iHeart App.

Connect

Explore

iHeart

Live Radio

Podcasts

Artist Radio

Exclusives

News

Features

Events

Contests

Photos

Information

About

Advertise

Blog

Brand Guidelines

Contest Guidelines

Subscription Offers

Jobs

Get the App

Automotive

Home

Mobile

Wearables

© 2025 iHeartMedia, Inc.